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Nerve growth factor is an essential neurotrophic
factor required for the growth and maintenance of
cutaneous sensory nerves. In the skin, keratinocytes
are a signi®cant source of nerve growth factor;
however, the regulation of cutaneous nerve growth
factor production still remains to be fully under-
stood. In this study we tested the hypothesis that
neuropeptides released by cutaneous sensory nerves
have the capacity to modulate directly the expression
of keratinocyte nerve growth factor, which would
have important implications for the maintenance and
repair of nerves in the skin. In order to address this
question experimentally we examined the effect of
the neuropeptides, substance P and neurokinin A, on
nerve growth factor expression in human keratino-
cytes and the murine keratinocyte PAM 212 cell line
by quantitative reverse transcriptase±polymerase
chain reaction, enzyme-linked immunosorbent assay,
and the PC-12 nerve growth factor bioassay. The
results of these studies indicated that substance P and
neurokinin A can directly induce nerve growth factor
mRNA expression and the secretion of bioactive
nerve growth factor protein in both human and
murine keratinocytes. The speci®city of these
responses was demonstrated using neuropeptide
receptor antagonists and nerve growth factor block-
ing antibodies. Additional studies also demonstrated
a signi®cant in vivo upregulation of keratinocyte
nerve growth factor expression in murine epidermis
after the topical application of the neuropeptide
releasing agent capsaicin. This is the ®rst report
demonstrating the induction of cutaneous nerve
growth factor by sensory nerve-derived neuropep-
tides such as substance P and neurokinin A. This
direct effect of the neurosensory system on keratino-
cyte nerve growth factor production may have
important consequences for the maintenance and
regeneration of cutaneous nerves in normal skin and
during in¯ammation and wound healing. Key words:
keratinocyte/nerve growth factor/neuroin¯ammation/neuro-
peptides. J Invest Dermatol 117:1075±1082, 2001
N
erve growth factor (NGF) is the ®rst isolated and
best characterized member of the neurotrophin
(NT) family of growth factors (Cohen et al, 1954;
Levi-Montalcini, 1987), which includes brain-
derived neurotrophic factor (BNDF) (Barde et al,
1982), NT-3 (Maisonpierre et al, 1990), NT-4 (Hallbook et al,
1991), and NT-5 (Berkemeier et al, 1991). NGF is detected in
neurons of the central and peripheral nervous system (Korsching
and Thoenen, 1983; Korsching et al, 1985; Heumann et al, 1987b)
as well as in a variety of other non-neuronal cell types such as B and
T lymphocytes (Santambrogio et al, 1994), mast cells (Leon et al,
1994), ®broblasts, and Schwann cells (Heumann et al, 1987a;
Matsuoka et al, 1991; Murase et al, 1992; Hattori et al, 1993). A
signi®cant source of NGF in normal skin appears to be
keratinocytes (Tron et al, 1990; Di Marco et al, 1991; Pincelli et
al, 1994). In addition, Langerhans cells (Torii et al, 1997) and
dermal microvascular endothelial cells (Gibran NS, 2000, personal
communication) have also been reported to express NGF in the
skin. There is increasing evidence that the development and
maintenance of the neurosensory system in the skin depends on the
localized expression of NGF (Otten et al, 1980; Ross et al, 1981;
Albers et al, 1994). Cutaneous NGF production may therefore
serve as a key factor in neuronal maintenance, survival, and repair
in the skin, especially during cutaneous in¯ammatory responses and
wound healing (reviewed in Pincelli and Yaar, 1997; Ansel et al,
1996).
It is now appreciated that the neurosensory system can modulate
a wide range of in¯ammatory and proliferative processes in various
tissues by the release of bioactive tachykinins such as substance P
(SP) and neurokinin A (NKA) (reviewed in Ansel et al, 1996, 1997;
Scholzen et al, 1998). Tachykinin releasing sensory C and Ad ®bers
extend from the dorsal root ganglia into the epidermis where they
are in direct contact with keratinocytes (Kennedy et al, 1994;
Lawson, 1996; Reilly et al, 1997; Schulze et al, 1997). Recent
evidence indicates that SP and NKA released into the skin after
injury can activate speci®c receptors on cutaneous target cells such
as dermal endothelial cells, Langerhans cells, and keratinocytes
thereby modulating cutaneous in¯ammation, wound healing, and
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tissue repair (reviewed in Scholzen et al, 1998). In experimental
models of in¯ammation, upregulation of neuropeptide levels in the
primary sensory neurons innervating the in¯amed tissue was
detected as well as elevated NGF levels in skin (Donnerer et al,
1992; Woolf et al, 1994; Sa®eh-Garabedian et al, 1995). Although it
has been reported that NGF upregulates neuropeptide levels in
nerves (Goedert et al, 1981), the ability of neuropeptides to induce
NGF production in skin tissue has not been studied. In this study
we test the hypothesis that neuropeptides released by cutaneous
sensory nerves may directly promote the local production of NGF,
which may be important during cutaneous injury and wound
healing.
The effects of SP and NKA are mediated by speci®c neurokinin
receptors that have been identi®ed on a number of cell types in the
skin, including human and murine keratinocytes. The functionality
of these keratinocyte neuropeptide receptors has been demon-
strated by neuropeptide induction of neurokinin receptor-mediated
speci®c Ca2+ mobilization and cytokine production in these cells
(Brown et al, 1990; Song et al, 1999). SP is known to preferentially
bind to the neurokinin 1 receptor (NK1R) and NKA to the
neurokinin 2 receptor (NK2R). As there is signi®cant cross-
reactivity of these ligand-receptor pairs, SP and NKA can bind to
both neurokinin receptors but with diminished af®nities (Regoli et
al, 1997). The murine keratinocyte cell line PAM 212 expresses
predominantly NK2R rather than NK1R and therefore both SP
and NKA appear to activate murine keratinocytes primarily by
activation of NK2R (Song et al, 1999). In contrast, human
keratinocytes express both NK1R and NK2R (Brown et al, 1990),
so SP and NKA stimulate speci®c responses through preferential
binding to these neurokinin receptors, respectively.
In this study we examined the ability of the sensory nerve-
derived neuropeptides SP and NKA to modulate keratinocyte NGF
expression in both human keratinocytes and the murine keratino-
cyte cell line PAM 212. Receptor blocking studies were conducted
to investigate the speci®city of our observations. Furthermore, the
effect of in vivo cutaneous neuropeptide release on keratinocyte
NGF production was determined.
MATERIALS AND METHODS
Cell culture conditions and reagents The spontaneously transformed
keratinocyte cell line (PAM 212), originally derived from a newborn
BALB/C mouse, was generously provided by Dr Stuart Yespa (National
Cancer Institute, Bethesda, MD). Cells were cultured in RPMI-1640
media (Mediatech Inc., Herndon, VA) containing 10% fetal bovine
serum (Gibco BRL/Life Technologies, Grand Island, NY) and 1%
penicillin±streptomycin amphotericin B (PSF, Gibco). Human
keratinocytes were isolated from neonatal foreskins at the Emory Skin
Diseases Research Core Center as previously described (Boyce and Ham,
1985) and cultured in keratinocyte growth media (Clonetics,
Walkersville, MD) supplemented with bovine pituitary extract
(Clonetics). PC-12 cells (American Type Culture Collection, ATCC,
Rockville, MD), originally derived from rat pheochromocytoma tissue,
were cultured in a medium of RPMI 1640, 10% donor horse serum
(Sigma, St Louis, MO), 5% fetal bovine serum, and 1% PSF. Cell
cultures were maintained at 37°C in humidi®ed incubators with 5%
CO2. PAM 212 cells and PC-12 cells were passaged at 60±70%
con¯uency to avoid differentiation. Human keratinocytes were cultured
until passages 3±5 for immediate use.
Before stimulating cells with various concentrations of neuropeptides,
proin¯ammatory stimuli, or conditioned media, human keratinocytes
were starved in keratinocyte growth media without bovine pituitary
extract; PAM 212 cells in RPMI-1640 media containing 1% fetal bovine
serum and 1% PSF; and PC-12 cells in RPMI-1640 media containing
1% donor horse serum, 0.5% fetal bovine serum, and 1% PSF for 24 h,
respectively. For quantitative polymerase chain reaction (PCR) and
enzyme-linked immunosorbent assay (ELISA) studies cells were either
left untreated or were treated with NKA or SP (Peninsula Laboratories,
Belmont, CA) in concentrations ranging from 0.1 to 100 nM. In some
studies, treatment with 50 ng per ml phorbol 12-myristate 13-acetate
(PMA, Sigma) served as a positive control. All mediators were diluted in
fresh starving media and added directly to the cells. Before stimulating
cells with 10 nM SP or NKA cells in selected studies were preincubated
for 30 min or 2 h either with a 10 mM solution of the speci®c NK1R
antagonist Spantide I (Peninsula; Yanagisawa and Otsuka, 1990) or a
1 mM solution of the speci®c NK2R antagonist GR-94800 (Peninsula;
McElroy et al, 1992), respectively. Spantide was dissolved in 1% acetic
acid, GR-94800 in 100% acetone and both were diluted to their ®nal
concentration in fresh starving media.
Quantitative reverse transcription±PCR Normal human
keratinocytes and murine PAM 212 cells were left untreated or treated
with neuropeptide concentrations ranging from 0.1 to 100 nm and
harvested after 3 h for total RNA isolation. This time-point was chosen
as preliminary experiments had demonstrated that NGF mRNA
expression after neuropeptide treatment was highest after 3 h (data not
shown). RNA was then subjected to DNAse treatment (Ambion, Austin,
TX) for 1 h at 37°C followed by a DNAse inactivation step at 70°C for
10 min and reverse transcribed using AMV reverse transcriptase
(Promega, Madison, WI) and random primers (Promega). cDNAs were
subjected to PCR utilizing the Perkin Elmer PCR 9600 sequence
detection system (Perkin Elmer Applied Biosystems, Foster City, CA)
and a SYBR green binding dye (Sybr Green PCR Core Reagents,
Perkin Elmer) (Morrison et al, 1998, 1999; Steuerwald et al, 2000). The
following speci®c NGF primers were selected using Primer Express
software (Perkin Elmer): human NGF sense primer 5¢-AAGTGCCGG-
GACCCAAAT-3¢; human NGF anti-sense primer 5¢-TGAGTTCCA-
GTGCTTTGAGTCAA-3¢; mouse NGF sense primer 5¢-ACAGTGTA-
TTCAGACAGTACTTTTTTGAGA-3¢; mouse NGF anti-sense primer
5¢-GAGTTCCAGTGTTTGGAGTCGAT-3¢; human and mouse 18 S
ribosomal RNA sense primer 5¢-CGGCTACCACATCCAAGGAA-3¢;
human and mouse 18 S ribosomal RNA anti-sense primer 5¢-
GCTGGAATTACCGCGGCT-3¢. For the ampli®cation of human NGF
cDNA a standard ampli®cation program was used (1 cycle of 50°C for
2 min, 1 cycle of 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C
for 1 min), for amplifying PAM 212 NGF cDNA the following
modi®cations were made: 1 cycle of 50°C for 2 min, 1 cycle of 95°C
for 10 min, 35 cycles of 95°C for 15 s and 60°C for 1 min. Direct
detection of the PCR product was monitored by measuring the increase
in ¯uorescence caused by the binding of SYBR green to double-
stranded DNA and the speci®city of the PCR product was veri®ed by
melting curve analysis (Ririe et al, 1997). The PCR product was
furthermore sequenced and compared with the published nucleotide
sequences verifying that the ampli®ed PCR product indeed corresponds
with the published NGF mRNA sequence (Ullrich et al, 1983; Borsani
et al, 1990). Using a standard curve of serial dilutions of an untreated
cDNA sample, a relative quantitation of the respective target cDNA
expressed in x-fold differences was performed. All quantitations were
normalized to an endogenous control (18S ribosomal RNA (Schmittgen
and Zakrajsek, 2000) to account for variability in the initial
concentration and quality of total RNA and in the conversion ef®ciency
of the reverse transcription reaction. Results are representative of three
independent assays.
PC-12 Bioassay To detect the presence of bioactive NGF in
untreated and neuropeptide-treated 48 h keratinocyte supernatants, PC-
12 bioassays were performed as previously described (Scott et al, 1981;
Varilek et al, 1991). Speci®cally, PC-12 cells were plated in 24-well
dishes at de®ned concentrations and stimulated with conditioned 48 h
supernatants from neuropeptide-treated keratinocytes after cell
attachment. In order to prove the speci®city of the bioassay,
neuropeptide-treated keratinocyte supernatants were preincubated with
speci®c anti-mouse and human NGF neutralizing antibodies (Roche
Diagnostics Corp., Indianapolis, IN) before stimulating PC-12 cells.
Untreated PC-12 cells served as a negative control and recombinant
NGF (50 mg per ml, Roche) treated PC-12 cells as a positive control.
After 48 h bioassays were quanti®ed by counting a minimum of 200 cells
in random ®elds per test well followed by determining the percentage of
cells bearing neurites. Cells were considered positive for neurite
outgrowth if they had one or more processes extending greater than one
cell diameter. Counts were done twice, results were calculated as mean
of counts and are representative of two independent assays.
ELISA studies and protein assay To quantitate secreted NGF by
ELISA, 48 h supernatants were collected from untreated and
neuropeptide-treated keratinocytes and utilized in a standard sandwich
ELISA (Promega). The 48 h time-point was chosen as preliminary
experiments had demonstrated that NGF protein secretion after
neuropeptide treatment was maximal after 48 h (data not shown).
Speci®cally, ¯at-bottom 96 well plates were coated using polyclonal anti-
human and mouse NGF antibodies. Captured NGF was detected by a
second speci®c monoclonal anti-NGF antibody and the amount of
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speci®cally bound monoclonal antibody was then detected using a
species-speci®c antibody conjugated to horseradish peroxidase as a
tertiary reactant. The unbound conjugate was removed by washing
followed by an incubation with the chromogenic substrate 3,3¢,5,5¢-
tetramethyl-benzidine. The colorimetric reaction was stopped by
addition of 50 ml 1 M H2SO4 and plates were read on an ELISA reader
(Spektramax 250, Molecular Devices Corp., Sunnyvale, CA) at OD
450 nm. A standard protein assay (Bio-Rad Laboratories, Hercules, CA)
was used for normalizing the NGF protein content of the supernatants to
the total cell lysate protein content. Data were analyzed utilizing Softmax
Pro (Molecular Devices Corp.) and Microsoft Excel (Microsoft Corp.,
Redmond, WA) software. Results were calculated as the mean of three
values 6 SD and are representative of three independent assays.
Statistical differences between NGF levels of untreated and treated
keratinocyte supernatants were calculated using unpaired Student's t test
and p < 0.05 was considered signi®cant.
Epicutaneous application of capsaicin Normal female C57BL/6
mice were obtained from Jackson Laboratories (Bar Harbor, ME) and
housed in the Emory Animal Facility. To cause the local release of
neuropeptides from sensory nerves in the skin, 8 wk old mice were
treated on the right ear with a single topical application of capsaicin
(Zostrix HP 0.075%); the left ear was not treated. Cutaneous treatment
sites and untreated control ears were collected from killed mice after 6,
12, 24, and 48 h, immediately frozen in OCT (Tissue-Tek, Sakura
Finetechnical, Torrance, CA) and stored at ±70°C. All animal procedures
were approved by the Institutional Animal Care and Use Committee
(IACUC) at Emory University (Atlanta, GA).
Immunohistochemistry Cryostat sections of untreated or capsaicin-
treated mouse skin (thickness: 8 mm) were ®xed in ice-cold acetone,
quenched in a 0.3% H2O2 solution and subjected to peroxidase
immunostaining using VectaStain elite ABC kit (Vector Laboratories
Inc., Burlingame, CA) according to the manufacturer's
recommendations. A polyclonal rabbit-anti-mouse-NGF antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) was used as a primary antibody
(1:100) and normal rabbit IgG (Santa Cruz Biotechnology) as a ®rst step
negative control at the same dilution. The primary antibody was
detected using a biotinylated goat-anti-rabbit antibody and a preformed
streptavidin horseradish peroxidase complex from the VectaStain elite
ABC kit. To prevent unspeci®c binding of the secondary antibody,
sections were blocked with 10% goat serum in Tris-buffered saline.
Sections were stained with a 3,3¢-diaminobenzidine solution (0.35 mg
per ml; Sigma FAST, Sigma) and counterstained with Mayer's
hematoxylin (Sigma). They were photographed with an Olympus C35
AD-4 camera, mounted on an Olympus BH2 microscope. Photographs
of immunohistochemistry sections were scanned on a ¯atbed scanner
(HP Scan Jet 6100 C, Hewlett Packard, Palo Alto, CA) utilizing Adobe
Photoshop software and printed on a high resolution laser printer (Kodak
Professional 8670 PS Thermal Printer, Eastman Kodak, Rochester, NY).
RESULTS
NGF mRNA expression is directly upregulated in human
and murine keratinocytes by SP and NKA To determine the
direct effect of neuropeptides on keratinocyte NGF mRNA
expression, SP or NKA (0.1±100 nM) were added to cultures of
normal human keratinocytes and murine PAM 212 keratinocytes
and mRNA expression was determined by quantitative reverse
transcriptase±PCR (Fig 1). SP was capable of directly upregulating
NGF mRNA expression in both human and murine keratinocytes
Figure 1. The neuropeptides SP and NKA
modulate NGF mRNA expression in human
and murine keratinocytes. Total RNA was
isolated from unstimulated cells and 3 h after
stimulating cells with 0.1±100 nM SP (A, B) or
NKA (C, D). RNA from either human (A, C) or
murine keratinocytes (B, D) was then reverse
transcribed and subjected to real-time quantitative
PCR analysis. PMA (50 ng per ml) treated
keratinocytes served as a positive control. To
determine the speci®city of the NGF mRNA
response, keratinocytes were pretreated with
selected neurokinin receptor antagonists
(NK1RA = Spantide I, NK2RA = GR-94800)
for 2 h and then exposed to SP or NKA
treatment at doses that generated the maximal
induction of NGF mRNA. The data shown are
representative of three independent experiments.
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(Fig 1A,B). In human keratinocytes, maximal NGF mRNA levels
were observed after the addition of 1 and 10 nm SP (Fig 1A),
whereas maximal PAM 212 NGF mRNA levels were detected
after the addition of 100 nM SP (Fig 1B). In addition to SP, NKA
was also effective in inducing NGF mRNA expression in both
human and murine keratinocytes with similar but not identical
dose±response curves (Figs 1C,D). In these studies PMA (50 ng
per ml) served as a positive control for the induction of keratinocyte
NGF mRNA (Fig 1A±D). The speci®city of the NGF PCR
product was veri®ed by melting curve analysis and sequencing as
described in Materials and Methods (data not shown). Additionally,
northern blot studies were carried out in selected experiments,
which con®rmed the quantitative reverse transcriptase±PCR results
(data not shown).
We then determined if the maximal neuropeptide induction of
keratinocyte NGF mRNA could be blocked by the addition of
speci®c neurokinin receptor (NKR) antagonists. Our results
indicated that the induction of keratinocyte NGF mRNA expres-
sion in murine PAM 212 keratinocytes by SP and NKA was
inhibited by pretreatment of the keratinocytes with the selective
NK2R antagonist GR 94800 (Figs 1B, D). This result is consistent
with the observation that PAM 212 cells express only the NK2R,
which is the principal receptor for NKA, but also can be activated
by SP, which binds to the NK2R with reduced af®nity compared
with the NK1R. In contrast to the murine cells, human
keratinocytes express both the NK1R and the NK2R. Our
blocking studies indicated that human keratinocyte NGF mRNA
expression stimulated by SP was only partly blocked by pretreat-
ment with the NK2R antagonist GR 94800 but completely
inhibited by pretreatment of cells with the NK1R antagonist
Spantide I (Fig 1A). Therefore, SP induction of human keratino-
cyte NGF occurs principally by activation of the NK1R (Fig 1A).
Our studies also demonstrated that the induction of human
keratinocyte NGF mRNA expression by NKA was only partly
blocked by pretreatment with the NK1R antagonist Spantide I, but
completely inhibited by pretreatment with the NK2R antagonist
GR94800, which is consistent with the fact that NKA primarily
binds and activates NK2R on human keratinocytes (Fig 1C).
SP and NKA induce the production of bioactive
keratinocyte NGF The effect of SP and NKA on the release
of bioactive NGF by murine and human keratinocytes was
determined. NGF protein bioactivity was measured in murine
and human keratinocyte supernatants of cultured cells treated for
48 h with 0.1±100 nM SP or NKA. Bioactivity was measured in
these conditioned keratinocyte supernatants in a standard NGF PC-
12 bioassay, which measures PC-12 dendrite growth in response to
exogenous NGF (Scott et al, 1981; Varilek et al, 1991). After 48 h,
PC-12 dendrite growth was quanti®ed by determining the
percentage of cells bearing neurites (Fig 2, representative
photomicrographs in Fig 3). As indicated in Fig 2, supernatants
from human and murine keratinocytes treated with SP or NKA
demonstrated notable NGF bioactivity compared with supernatants
from the untreated cells. Conditioned supernatants from SP-treated
human keratinocytes induced a 15±26% increase in PC-12 dendrite
Figure 2. Bioactive NGF is secreted by
human and murine keratinocytes following
SP or NKA treatment. PC-12 cells were treated
with 48 h supernatants from human (A and C) or
mouse keratinocytes (B, D), which were exposed
to concentrations of SP (A, B) and NKA (C, D)
ranging from 0.1 to 100 nM or left untreated.
Untreated PC-12 cells served as a negative
control; recombinant NGF (50 mg per ml) was
added to PC-12 cells to serve as a positive
control. The PC-12 cell response was quanti®ed
after 48 h by determining the percentage of cells
bearing neurites. ``Medium'' indicates untreated
PC-12 cells. ``Untreated'' indicates treatment of
PC-12 cells with untreated keratinocyte
supernatant. To demonstrate the speci®city of the
response, supernatants from neuropeptide-treated
keratinocytes (10 nM SP and 10 nM NKA,
respectively) were preincubated with speci®c anti-
human and mouse NGF neutralizing antibody
before stimulating PC-12 cells. The data shown
are representative of two independent experiments
with two independent counts, respectively.
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growth when compared with dendrite growth in PC-12 cells that
were exposed to medium alone (Figs 2A and 3A). The optimal
dose for inducing this result was 10 nM SP. In contrast, conditioned
supernatants from SP-treated murine PAM 212 keratinocyte
cultures induced a 7±13% increase in PC-12 dendrite growth
with an optimal response occurring after treatment of cells with
100 nM SP (Fig 2B). The effect of NKA on human and murine
keratinocyte NGF bioactivity was then measured. Conditioned
supernatants from NKA-treated human keratinocytes demonstrated
an induction of dendrite growth by 8±14% compared with PC-12
cells exposed to medium alone (Fig 2C). Likewise, conditioned
supernatants from NKA-treated murine PAM 212 keratinocytes
induced PC-12 dendrite growth by 15±38% with an optimal
response to 10 nM NKA-treated PAM 212 keratinocyte
supernatants (Fig 2D). As indicated in Fig 2, the increase in PC-
12 dendrite growth in the murine and human studies was
speci®cally blocked by preincubating keratinocyte conditioned
supernatants with neutralizing human and mouse NGF antibodies,
thus demonstrating the NGF speci®city of this response (Figs 2A±
D and 3B). PC-12 cells treated with medium alone served as a
negative control and recombinant NGF-treated PC-12 cells served
as a positive control for these studies (Figs 2A±D and 3C, D).
The amount of NGF protein present in untreated or neuropep-
tide-treated keratinocyte supernatants was then quanti®ed by
ELISA. Consistent with our previous PC-12 bioassay studies, a
neuropeptide concentration-dependent response curve was dem-
onstrated for secreted NGF in 48 h supernatants of SP-treated
human keratinocytes with an optimal response after stimulating the
keratinocytes with 10 nM SP (Fig 4A, up to 75 pg per ml). NKA
was capable of stimulating NGF protein secretion up to 45 pg per
ml in murine PAM 212 keratinocytes in a concentration-depend-
ent manner with an optimal response observed after the addition of
10 nM NKA to the cultured cells (Fig 4B). ELISA results with
NKA-treated human and SP-treated murine keratinocyte super-
natants were consistent with our previous bioactivity studies (data
not shown). Statistically signi®cant differences were demonstrated
for the NGF protein content in all neuropeptide-treated keratino-
cyte supernatants over the respective untreated cell supernatants
Figure 4. Quanti®cation of secreted NGF
protein after neuropeptide treatment of
human and murine keratinocytes by ELISA.
Human keratinocytes were stimulated with 0.1±
100 nM SP (A) and the murine PAM 212
keratinocyte cell line was stimulated with 0.1±
100 nM NKA (B) or left untreated for 48 h at
37°C. PMA-treated human and murine
keratinocytes served as a positive control. NGF
concentrations in the supernatants were measured
by ELISA and results were normalized against
total protein concentrations in the respective cell
lysates. The speci®city of the NGF protein
response was tested by pretreating keratinocytes
with speci®c neurokinin receptor antagonists
(NK1RA = Spantide I, NK2RA = GR-94800)
for 2 h before exposing them to SP or NKA
treatment. Statistically signi®cant differences
between NGF concentrations in samples from
treated and untreated cells were determined by
Student's t test as indicated by * (p < 0.05). The
data shown are representative of three
independent experiments conducted in triplicate.
Figure 3. PC-12 cells form dendrites in the
presence of conditioned keratinocyte
supernatants. PC-12 cells were left untreated
(D) or were stimulated with 48 h supernatants
from human keratinocytes exposed to 10 nM SP
(A). To demonstrate the speci®city of the
response, the 10 nM SP-conditioned supernatant
was preincubated with a speci®c neutralizing anti-
human NGF antibody before stimulating the PC-
12 cells (B). Treatment of PC-12 cells with
recombinant NGF (50 mg per ml) served as a
positive control (C). Arrows indicate dendrite
growth. Scale bar : 6 mm.
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(Fig 4A, B). Again, PMA-treated human and murine keratinocytes
served as a positive control for these studies (Fig 4A, B). The
induction of NGF protein secretion by SP was abrogated in human
keratinocytes by pretreatment of cells with the speci®c NK1R
antagonist Spantide I (Fig 4A). In murine PAM 212 keratinocytes
the induction of NGF secretion by NKA was speci®cally inhibited
to control levels by pretreatment with the NK2R antagonist
(Fig 4B).
Capsaicin-induced neuropeptide release results in increased
epidermal NGF To determine if neuropeptides are capable of
upregulating epidermal NGF expression in vivo, C57BL/6 mouse
ear skin was left untreated or treated topically with capsaicin
(0.075%, Zostrix HP), which causes the local release of
neuropeptides from sensory nerves in the skin. After collecting
tissue at 6, 12, 18, 24, and 48 h, cryostat sections were subjected to
peroxidase immunostaining using a speci®c anti-murine NGF
antibody. A faint constitutive NGF expression was observed in the
keratinocyte cytoplasm of untreated epidermis (Fig 5A) with some
increase in staining 24 h after capsaicin application (Fig 5B). There
was a marked increase in NGF expression in murine epidermal
keratinocytes 48 h after capsaicin treatment (Fig 5C). In Fig 5D,
capsaicin-treated ear skin was incubated with normal rabbit serum
instead of primary antibody thereby serving as a negative control for
these studies. Quantitative reverse transcriptase±PCR data
demonstrated that NGF mRNA levels were not upregulated in
capsaicin-treated keratinocytes when compared with NGF mRNA
levels in untreated keratinocytes (data not shown) suggesting that
keratinocyte NGF induction is rather due to a capsaicin-induced
neuropeptide release than a direct capsaicin effect.
DISCUSSION
NGF is an important molecule in the cutaneous microenviron-
ment, where it may modulate in¯ammatory responses, cellular
growth, and nerve maintenance and repair in skin (reviewed in
Ansel et al, 1996; Pincelli and Yaar, 1997). Various growth factors
and cytokines (Lindholm et al, 1988, 1990) as well as b-adrenergic
compounds (Carswell et al, 1992) appear to modulate NGF
expression in many noncutaneous tissues. In the skin, proin¯am-
matory stimuli such as phorbol ester and ultraviolet B irradiation
have been reported to upregulate the expression of keratinocyte
NGF (Tron et al, 1990). Likewise, epidermal barrier disruption by
tape stripping or acetone treatment can induce the expression of
NGF in murine epidermis (Liou et al, 1997). Furthermore,
signi®cant upregulation of keratinocyte NGF was observed after
viral transformation with the human papillomavirus 16, whereas
transformation with the simian virus SV40, which induces simple
epithelial differentiation, reduces the expression of NGF (Anand et
al, 1995). In cultured human keratinocytes NGF expression is
strongly inhibited by the addition of hydrocortisone (Di Marco et
al, 1991). Neuropeptide induction of NGF has not been demon-
strated in noncutaneous tissue or in the skin.
In this study we demonstrate that cutaneous sensory nerve-
derived neuropeptides, which are released into the skin during
in¯ammation or injury, can directly modulate NGF expression in
keratinocytes. The neuropeptides SP and NKA were effective in
stimulating NGF mRNA expression in human and murine
keratinocytes. Whereas SP induced a concentration-dependent
increase in human keratinocyte NGF production, murine kerati-
nocytes demonstrated a maximal NGF mRNA response only after
exposure to higher SP concentrations. NKA also induced a
concentration-dependent increase in both human and murine
keratinocyte NGF. We have previously reported that in contrast to
human keratinocytes, which express both the SP high-af®nity
NK1R and lesser amounts of NK2R, murine PAM 212
keratinocytes express NK2R but not NK1R (Brown et al, 1990;
Song et al, 1999). Therefore, human keratinocytes can respond to
either SP or NKA by activation of their respective high-af®nity
receptors NK1R and NK2R. This was supported by receptor
blocking studies, which demonstrated that SP primarily binds to
NK1R and that NKA principally binds to NK2R in human
keratinocytes. As murine keratinocytes only express the NK2R, the
relative bioactivity of NKA is higher than SP for the induction of
NGF in these cells. Both SP- and NKA-induced NGF mRNA
responses are reduced by preincubation with a speci®c NK2RA.
Understanding this particular species speci®c difference in neuro-
kinin receptor distribution and respective neuropeptide af®nities in
human and murine keratinocytes will facilitate our ability to study
the effect of neuropeptide-induced mediators, including NGF in
cell culture and in animal models.
This study also demonstrated the presence of bioactive NGF
protein in human and murine keratinocyte supernatants that
induced signi®cant dendrite growth in PC-12 cells (PC-12
bioassays). Quanti®cation of NGF protein in the same keratinocyte
Figure 5. NGF protein expression in
individual mouse skin keratinocytes is
increased after capsaicin application. C57BL/
6 mouse ear skin was either left untreated (A) or
treated with topical capsaicin to cause the release
of neuropeptides from sensory nerves (B and C).
Treated skin was collected after 6 h, 12 h (data
not shown), 24 h (B), and 48 h (C) and subjected
to peroxidase immunostaining using speci®c anti-
mouse NGF antibodies. Capsaicin-treated skin
incubated with normal rabbit IgG instead of ®rst
antibody served as a negative control (D). Arrows
point to speci®c intracellular NGF staining.
Treated skin, which was collected after 6 and
12 h did not show elevated epidermal NGF levels
when compared with untreated skin. Scale bar :
6 mm.
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supernatants by ELISA revealed that very small quantities (up to
75 pg per ml) are suf®cient to induce a signi®cant biologic
response. Furthermore, the ELISA studies corresponded to and
con®rmed the pattern of dendrite growth induction observed in
respective PC-12 bioassays. The ELISA studies also demonstrated
that NGF protein levels were reduced by preincubation with
speci®c neurokinin receptor antagonists; however, the relatively
long time period between optimal keratinocyte NGF mRNA
induction 3 h after neuropeptide treatment and maximal bioactive
NGF protein secretion at 48 h may indicate the participation of
other nontachykinin mediators in inducing keratinocyte NGF
protein secretion. Although an involvement of other neuropeptide
or non-neuropeptide mediators can also not be excluded in our
in vivo studies demonstrating an upregulation of NGF protein
expression in capsaicin-treated mouse skin, it is very likely that
sensory-nerve derived substance P and neurokinin A participate in
this response. Thus, both our in vivo and in vitro data demonstrating
the induction of NGF protein by neuropeptides in human and
murine keratinocytes strongly support the importance of our
®ndings for the biology of skin.
Denervation of normally innervated skin results in signi®cantly
delayed wound healing (Engin et al, 1996; Richards et al, 1997).
Keratinocyte NGF expression increases during wound healing1 and
external treatment with recombinant NGF on wounds accelerates
the wound healing process (Li et al, 1980; Matsuda et al, 1998;
Bernabei et al, 1999). In diseases such as leprosy and diabetes, which
lead to an impairment of the cutaneous sensory nervous system,
epidermal keratinocytes show a depletion of NGF (Anand et al,
1994, 1996). Furthermore, diabetic mice show decreased sciatic
nerve neuropeptide levels and in skin biopsies of neuropathic areas
in diabetic patients a reduction of neuropeptide containing nerves
can be seen (Tomlinson et al, 1988; Willars et al, 1989; Levy et al,
1992; Fernyhough et al, 1994). Our studies indicate that there may
be a bidirectional relationship between keratinocytes and cutaneous
nerves. The new concept that neuropeptides can induce the
expression of NGF and, conversely, that an absence of neuropep-
tides or neuropeptide releasing neurons may lead to decreased levels
of NGF may explain, at least in part, the pathophysiologic ®ndings
in some peripheral neuropathies.
The results of this study suggest a novel regulatory pathway
where cutaneous neuropeptides, which are released after an
injurious stimulus from skin nerves, upregulate keratinocyte NGF
expression that in turn may regulate nerve repair and regrowth.
This concept of direct in¯uence of the cutaneous sensory nervous
system on the regulation of keratinocyte NGF contributes signi®-
cantly to the understanding of skin biology under physiologic
conditions and during disease.
This work was supported in part by grants from the National Institutes of Health
(NIH HD33024 and NIH AI4193 to J.C.A., NIH R03AR44969 to
C.A.A.), a Veterans Affairs Merit Review grant to J.C.A. and fellowship grants
from the Deutsche Forschungsgemeinschaft and the Dermatology Foundation to
G.J.B. The assistance of Katherine A. Casper (Emory University) in quantitative
reverse transcriptase±PCR studies and of Marcia Usui (University of Washington,
Seattle) in immunohistochemistry studies is gratefully acknowledged.
REFERENCES
Albers KM, Wright DE, Davis BM: Overexpression of nerve growth factor in
epidermis of transgenic mice causes hypertrophy of the peripheral nervous
system. J Neurosci 14:1422±1432, 1994
Anand P, Pandya S, Ladiwala U, Singhal B, Sinicropi DV, Williams-Chestnut RE:
Depletion of nerve growth factor in leprosy [letter]. Lancet 344:129±130, 1994
Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi
DV: The role of endogenous nerve growth factor in human diabetic
neuropathy. Nature Med 2:703±707, 1996
Anand P, Foley P, Navsaria HA, Sinicropi D, Williams-Chestnut RE, Leigh IM:
Nerve growth factor levels in cultured human skin cells. effect of gestation and
viral transformation. Neurosci Lett 184:157±160, 1995
Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D:
Skin±nervous system interactions. J Invest Dermatol 106:198±204, 1996
Ansel JC, Armstrong CA, Song I, Quinlan KL, Olerud JE, Caughman SW, Bunnett
NW: Interactions of the skin and nervous system. J Invest Dermatol Symp Proc
2:23±26, 1997
Barde YA, Edgar D, Thoenen H: Puri®cation of a new neurotrophic factor from
mammalian brain. EMBO J 1:549±553, 1982
Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A:
Neurotrophin-5. a novel neurotrophic factor that activates trk and trkB. Neuron
7:857±866, 1991
Bernabei R, Landi F, Bonini S, Onder G, Lambiase A, Pola R, Aloe L: Effect of
topical application of nerve-growth factor on pressure ulcers. Lancet 354:307,
1999
Borsani G, Pizzuti A, Rugarli EI, et al: cDNA sequence of human beta-NGF. Nucleic
Acids Res 18:4020, 1990
Boyce ST, Ham RG: Cultivation, frozen storage, and clonal growth of normal
human epidermal keratinocytes in serum free media. J Tissue Culture Methods
9:83, 1985
Brown JR, Perry P, Hefeneider S, Ansel JC: Neuropeptide modulation of
keratinocyte cytokine production. In: Oppenheim JJ, Powanda MC,
Kluger M, Dinarello CA (eds). Molecular and Cellular Biology of Cytokines.
Wiley-Liss, Inc., Somerset, NJ, 1990, pp 451±456
Carswell S, Hoffman EK, Clopton-Hartpence K, Wilcox HM, Lewis ME: Induction
of NGF by isoproterenol, 4-methylcatechol and serum occurs by three distinct
mechanisms. Brain Res Mol Brain Res 15:145±150, 1992
Cohen S, Levi-Montalcini R, Hamburger V: A nerve growth stimulating factor
isolated from sarcoma 37 and 180. Proc Natl Acad Sci USA 40:1014±1018, 1954
Di Marco E, Marchisio PC, Bondanza S, Franzi AT, Cancedda R, De Luca M:
Growth-regulated synthesis and secretion of biologically active nerve growth
factor by human keratinocytes. J Biol Chem 266:21718±21722, 1991
Donnerer J, Schuligoi R, Stein C: Increased content and transport of substance P and
calcitonin gene-related peptide in sensory nerves innervating in¯amed tissue:
evidence for a regulatory function of nerve growth factor in vivo. Neuroscience
49:693±698, 1992
Engin C, Demirkan F, Ayhan S, Atabay K, Baran NK: Delayed effect of denervation
on wound contraction in rat skin. Plast Reconstr Surg 98:1063±1067, 1996
Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR: De®cits in sciatic nerve
neuropeptide content coincide with a reduction in target tissue nerve growth
factor messenger RNA in streptozotocin-diabetic rats. effects of insulin
treatment. Neuroscience 62:337±344, 1994
Goedert M, Stoeckel K, Otten U: Biological importance of the retrograde axonal
transport of nerve growth factor in sensory neurons. Proc Natl Acad Sci USA
78:5895±5898, 1981
Hallbook F, Ibanez CF, Persson H: Evolutionary studies of the nerve growth factor
family reveal a novel member abundantly expressed in Xenopus ovary. Neuron
6:845±858, 1991
Hattori A, Tanaka E, Murase K, et al: Tumor necrosis factor stimulates the synthesis
and secretion of biologically active nerve growth factor in non-neuronal cells. J
Biol Chem 268:2577±2582, 1993
Heumann R, Korsching S, Bandtlow C, Thoenen H: Changes of nerve growth
factor synthesis in nonneuronal cells in response to sciatic nerve transection. J
Cell Biol 104:1623±1631, 1987a
Heumann R, Lindholm D, Bandtlow C, et al: Differential regulation of mRNA
encoding nerve growth factor and its receptor in rat sciatic nerve during
development, degeneration, and regeneration: role of macrophages. Proc Natl
Acad Sci USA 84:8735±8739, 1987b
Kennedy WR, Wendelschafer-Crabb G, Brelje TC: Innervation and vasculature of
human sweat glands: an immunohistochemistry-laser scanning confocal
¯uorescence microscopy study. J Neurosci 14:6825±6833, 1994
Korsching S, Thoenen H: Nerve growth factor in sympathetic ganglia and
corresponding target organs of the rat: correlation with density of
sympathetic innervation. Proc Natl Acad Sci USA 80:3513±3516, 1983
Korsching S, Auburger G, Heumann R, Scott J, Thoenen H: Levels of nerve growth
factor and its mRNA in the central nervous system of the rat correlate with
cholinergic innervation. EMBO J 4:1389±1393, 1985
Lawson SN: Peptides and cutaneous polymodal nociceptor neurones. Prog Brain Res
113:369±385, 1996
Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R:
Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci
USA 91:3739±3743, 1994
Levi-Montalcini R: The nerve growth factor: thirty-®ve years later. [published
erratum appears in EMBO J 6(9):2856, 1987.]. EMBO J 6:1145±1154, 1987
Levy DM, Terenghi G, Gu XH, Abraham RR, Springall DR, Polak JM:
Immunohistochemical measurements of nerves and neuropeptides in diabetic
skin: relationship to tests of neurological function. Diabetologia 35:889±897,
1992
Li AK, Koroly MJ, Schattenkerk ME, Malt RA, Young M: Nerve growth factor.
acceleration of the rate of wound healing in mice. Proc Natl Acad Sci USA
77:4379±4381, 1980
Lindholm D, Heumann R, Hengerer B, Thoenen H: Interleukin 1 increases stability
and transcription of mRNA encoding nerve growth factor in cultured rat
®broblasts. J Biol Chem 263:16348±16351, 1988
Lindholm D, Hengerer B, Zafra F, Thoenen H: Transforming growth factor-beta 1
1Burbach GJ, Kim K, Zivony AS, et al: The expression and regulation of
keratinocyte nerve growth factor during cutaneous wound healing. J Invest
Dermatol 114:800, 2000 (abstr.)
VOL. 117, NO. 5 NOVEMBER 2001 NEUROPEPTIDE INDUCTION OF KERATINOCYTE NGF 1081
stimulates expression of nerve growth factor in the rat CNS. Neuroreport 1:9±12,
1990
Liou A, Elias PM, Grunfeld C, Feingold KR, Wood LC: Amphiregulin and nerve
growth factor expression are regulated by barrier status in murine epidermis. J
Invest Dermatol 108:73±77, 1997
Maisonpierre PC, Belluscio L, Squinto S, et al: Neurotrophin-3: a neurotrophic
factor related to NGF and BDNF. Science 247:1446±1451, 1990
Matsuda H, Koyama H, Sato H, et al: Role of nerve growth factor in cutaneous
wound healing: accelerating effects in normal and healing-impaired diabetic
mice. J Exp Med 187:297±306, 1998
Matsuoka I, Meyer M, Thoenen H: Cell-type-speci®c regulation of nerve growth
factor (NGF) synthesis in non-neuronal cells: comparison of Schwann cells
with other cell types. J Neuroscience 11:3165±3177, 1991
McElroy AB, Clegg SP, Deal MJ, et al: Highly potent and selective heptapeptide
antagonists of the neurokinin NK-2 receptor. J Med Chem 35:2582±2591, 1992
Morrison TB, Weis JJ, Wittwer CT: Quanti®cation of low-copy transcripts by
continuous SYBR Green I monitoring during ampli®cation. Biotechniques
24:954±958, 960, 962, 1998
Morrison TB, Ma Y, Weis JH, Weis JJ: Rapid and sensitive quanti®cation of Borrelia
burgdorferi-infected mouse tissues by continuous ¯uorescent monitoring of
PCR. J Clin Microbiol 37:987±992, 1999
Murase K, Murakami Y, Takayanagi K, Furukawa Y: Hayashi. Human ®broblast cells
synthesize and secrete nerve growth factor in culture. Biochem Biophys Res
Commun 184:373±379, 1992
Otten U, Goedert M, Mayer N, Lembeck F: Requirement of nerve growth factor for
development of substance P-containing sensory neurones. Nature 287:158±159,
1980
Pincelli C, Yaar M: Nerve growth factor: its signi®cance in cutaneous biology.
[Review]. J Invest Dermatol Symp Proc 2:31±36, 1997
Pincelli C, Sevignani C, Manfredini R, et al: Expression and function of nerve
growth factor and nerve growth factor receptor on cultured keratinocytes. J
Invest Dermatol 103:13±18, 1994
Regoli D, Nguyen K, Calo G: Neurokinin receptors. Comparison of data from
classical pharmacology, binding, and molecular biology. Ann N Y Acad Sci
812:144±146, 1997
Reilly DM, Ferdinando D, Johnston C, Shaw C, Buchanan KD, Green MR: The
epidermal nerve ®bre network. characterization of nerve ®bres in human skin
by confocal microscopy and assessment of racial variations. Br J Dermatol
137:163±170, 1997
Richards AM, Mitsou J, Floyd DC, Terenghi G, McGrouther DA: Neural
innervation and healing [letter]. Lancet 350:339±340, 1997
Ririe KM, Rasmussen RP, Wittwer CT: Product differentiation by analysis of DNA
melting curves during the polymerase chain reaction. Anal Biochem
245:154±160, 1997
Ross M, Lofstrandh S, Gorin PD, Johnson EM, Schwartz JP: Use of an experimental
autoimmune model to de®ne nerve growth factor dependency of peripheral
and central substance P-containing neurons in the rat. J Neurosci 1:1304±1311,
1981
Sa®eh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ: Contribution of
interleukin-1 beta to the in¯ammation-induced increase in nerve growth factor
levels and in¯ammatory hyperalgesia. Br J Pharmacol 115:1265±1275, 1995
Santambrogio L, Benedetti M, Chao MV, Muzaffar R, Kulig K, Gabellini N,
Hochwald G: Nerve growth factor production by lymphocytes. J Immunol
153:4488±4495, 1994
Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping
gene expression: validation by real-time, quantitative RT-PCR [In Process
Citation]. J Biochem Biophys Methods 46:69±81, 2000
Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC:
Neuropeptides in the skin. interactions between the neuroendocrine and the
skin immune systems. [Review]. Exp Dermatol 7:81±96, 1998
Schulze E, Witt M, Fink T, Hofer A, Funk RH: Immunohistochemical detection of
human skin nerve ®bers. Acta Histochem 99:301±309, 1997
Scott SM, Tarris R, Eveleth D, Mans®eld H, Weichsel MEJ, Fisher DA: Bioassay
detection of mouse nerve growth factor (mNGF) in the brain of adult mice. J
Neurosci Res 6:653±658, 1981
Song IS, Bunnett NW, Olerud JE, et al: Substance P induction of murine
keratinocyte PAM 212 interleukin 1 production is mediated by the
neurokinin-2 receptor (NK-2R). Exp Dermatol 9:42±52, 2001
Steuerwald N, Cohen J, Herrera RJ, Brenner CA: Quanti®cation of mRNA in single
oocytes and embryos by real-time rapid cycle ¯uorescence monitored RT-
PCR. Mol Hum Reprod 6:448±453, 2000
Tomlinson DR, Robinson JP, Willars GB, Keen P: De®cient axonal transport of
substance P in streptozotocin-induced diabetic rats. Effects of sorbinil and
insulin. Diabetes 37:488±493, 1988
Torii H, Yan Z, Hosoi J, Granstein RD: Expression of neurotrophic factors and
neuropeptide receptors by Langerhans cells and the Langerhans cell-like cell
line XS52: further support for a functional relationship between Langerhans
cells and epidermal nerves. J Invest Dermatol 109:586±591, 1997
Tron VA, Coughlin MD, Jang DE, Stanisz J, Sauder DN: Expression and modulation
of nerve growth factor in murine keratinocytes (PAM 212). J Clin Invest
85:1085±1089, 1990
Ullrich A, Gray A, Berman C, Dull TJ: Human beta-nerve growth factor gene
sequence highly homologous to that of mouse. Nature 303:821±825, 1983
Varilek GW, Weinstock JV, Pantazis NJ: Isolated hepatic granulomas from mice
infected with Schistosoma mansoni contain nerve growth factor. Infect Immun
59:4443±4449, 1991
Willars GB, Calcutt NA, Compton AM, Tomlinson DR, Keen P: Substance P levels
in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats
with long-term diabetes mellitus. Effects of aldose reductase inhibition. J Neurol
Sci 91:153±164, 1989
Woolf CJ, Sa®eh-Garabedian B, Ma QP, Crilly P, Winter J: Nerve growth factor
contributes to the generation of in¯ammatory sensory hypersensitivity.
Neuroscience 62:327±331, 1994
Yanagisawa M, Otsuka M: Pharmacological pro®le of a tachykinin antagonist,
spantide, as examined on rat spinal motoneurons. Br J Pharmacol 100:711±706,
1990
1082 BURBACH ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
